STOCK TITAN

Therapeutic Solutions International Inc - TSOI STOCK NEWS

Welcome to our dedicated news page for Therapeutic Solutions International (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Therapeutic Solutions International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Therapeutic Solutions International's position in the market.

Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) announces the granting of a patent for QuadraMune® to stimulate natural killer (NK) cell activity in COVID-19 patients. The patent covers immune suppression inhibition, SARS-CoV-2 prevention, brain protection, and T regulatory cell upregulation. The Company aims to address medical needs through innovative therapies and nutraceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
covid-19
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) announces groundbreaking results in experiments showing the healing effects of JadiCells involve an interplay between immunological cells. The data suggests that JadiCells amplify therapeutic effects through monocytes and T cells expressing specific molecules, with potential applications in lung diseases like ARDS and COVID-19. The Company is progressing towards Phase III trials for COVID-19 and ARDS, aiming to revolutionize treatment standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) reveals groundbreaking data showing enhanced gene therapy effects with JadiCell administration. The company demonstrated a significant increase in therapeutic cell production by combining gene therapy with JadiCell, particularly effective in treating hormone-producing cell deficiencies. Dr. Thomas Ichim and Timothy Dixon express optimism about the potential impact on clinical translation and seek collaborators for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
none
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) has filed a Civil Action in the Superior Court of the State of California to disclose the identities of individuals posting defamatory statements on StockTwits. The company seeks to enjoin further defamatory communications and recover from significant injuries. StockTwits, InvestorsHub, and Yahoo message boards are targeted for allowing users to post anonymously, potentially leading to fraud and stock market manipulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) has formed Epilepsy Bio, Inc., a subsidiary company dedicated to commercializing intellectual property, clinical, and mechanistic findings associated with cellular and immunological approaches to epilepsy. The company successfully treated an advanced epilepsy patient using its patented JadiCell universal donor stem cell product and plans to change the standard of care for some subsets of epilepsy patients. The global epilepsy market size was valued at USD 2.61 billion in 2021 and expected to reach USD 4.70 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) successfully treated four advanced cancer patients with FloraStilbene™, a drug comprising the abortion pill's active ingredient and pterostilbene. No adverse events were observed, and clinical signals of tumor response were noted. The drug has shown efficacy in stimulating immune responses in animal models of various cancers, with emphasis on triple negative breast tumor models. The use of pterostilbene for cancer immunotherapy was patented by the company. The data from this treatment will serve as the basis for future clinical trials for FDA sales approval. The company has the support of leaders of the Pro-Life Movement. The rapid translation of FloraStilbene™ from a laboratory discovery to a compounded drug speaks volumes to the power of the company's team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) announced the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of assets related to Amyotrophic Lateral Sclerosis. The company aims to improve outcomes for ALS patients and eventually cure the disease by leveraging previous positive patient experiences with the ALScell™ (JadiCell™) product under the Right to Try Law. The company plans to file for IND for ALS treatment by the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) announced a publication with Campbell Neurosciences and academic institutions regarding the modulation of the indolamine 2,3 dioxygenase pathway in depression by QuadraMune®, a patented nutraceutical. The publication highlights the potential of QuadraMune® in treating major depressive disorder, addressing the 'Silent Epidemic' of depression resistant to conventional medication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) announced the publication of a peer-reviewed paper on personalized immunotherapy for brain cancer. The paper discusses advances in stimulating cancer-specific and patient-specific immunity, integrating immunotherapy with other approaches, and the advantages of mRNA immunization. The company is developing clinical-stage immune-oncology assets through the spin-off Res Nova Biologics, treating cancer patients with its ValloVax and FloraStilbene products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Therapeutic Solutions International's immuno-oncology subsidiary, Res Nova Bio, has successfully treated a patient with FloraStilbene™, a formulation of the abortion pill's active ingredient and pterostilbene.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
Therapeutic Solutions International Inc

OTC:TSOI

TSOI Rankings

TSOI Stock Data

2.89M
2.90B
20.03%
Tobacco Manufacturing
Manufacturing
Link
United States
Elk City